Gut microbiome-specific nanoparticle-based therapeutics for liver diseases

doi:10.3748/wjg.v31.i27.109105

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (42)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-1)

Sum=41

Jul 21, 2025 (publication date) through Jul 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 21, 2025; 31(27): 109105
Published online Jul 21, 2025. doi: 10.3748/wjg.v31.i27.109105

Gut microbiome-specific nanoparticle-based therapeutics for liver diseases

Amit Khurana, Phillipp Hartmann

Amit Khurana, Phillipp Hartmann, Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, United States

Author contributions: Khurana A wrote the manuscript; Hartmann P supervised the work and edited the manuscript. All authors have approved the submitted version.

Supported by University of California San Diego Altman Clinical and Translational Research Institute, No. KL2TR001444; 2022 Pinnacle Research Award in Liver Diseases from the American Association for the Study of Liver Diseases Foundation, No. PNC22-159963; and National Institutes of Health, No. P30 DK120515.

Conflict-of-interest statement: Phillipp Hartmann’s institution University of California San Diego has received grant support from Nterica Bio, Inc. The authors do not have any competing interests related to this manuscript.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Phillipp Hartmann, MD, Assistant Professor, Department of Pediatrics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. phhartmann@health.ucsd.edu

Received: April 29, 2025
Revised: May 29, 2025
Accepted: June 30, 2025
Published online: July 21, 2025
Processing time: 83 Days and 10.4 Hours

Core Tip

Core Tip: Chronic liver diseases are driven by metabolic, immune, and microbiome dysregulation. In this review, we detail recent advances in nanomedicine that enable tailored modulation of the gut microbiota, which can improve chronic liver diseases. Nanoparticles increase pharmacological effects and can reduce off-target effects. Further, artificial intelligence and machine learning can aid in production of precision nanomedicine.